Author + information
- Sanjum S. Sethi, MD, MPH∗ (, )@sanjum,
- Robert Zilinyi, MD,
- Philip Green, MD,
- Andrew Eisenberger, MD,
- Daniel Brodie, MD,
- Cara Agerstrand, MD,
- Koji Takeda, MD,
- Ajay J. Kirtane, MD, SM,
- Sahil A. Parikh, MD,
- Erika B. Rosenzweig, MD,
- for the CUIMC PERT team
- ↵∗Corresponding Author: Sanjum S. Sethi MD, MPH Assistant Professor of Medicine, Center for Interventional Vascular Therapy 161 Fort Washington Ave Fl 6 New York, NY 10032 212 305 7060 ., Twitter: .
Severe acute respiratory syndrome coronavirus 2 is associated with a prothrombotic state in infected patients. After presenting a case of right ventricular thrombus in a COVID-19 patient, we discuss the unique challenges in the workup and treatment of COVID-19 patients highlighting our COVID-19 modified pulmonary embolism response team (PERT) algorithm.
Disclosures: Sanjum S. Sethi reports honoraria from Chiesi, Inc and Janssen.
Daniel Brodie reports research support from ALung Technologies, he was previously on their medical advisory board. He has been on the medical advisory boards for Baxter, BREETHE, Xenios and Hemovent.
Ajay Kirtane reports Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for speaking engagements and/or consulting; no speaking/consulting fees were personally received. Personal: Travel/Meal reimbursements only.
Sahil A. Parikh reports institutional grants/research support from Abbott Vascular, Shockwave Medical, TriReme Medical and Surmodics; consulting fees from Terumo and Abiomed; and Advisory Board participation for Abbott, Medtronic, Boston Scientific, CSI, Janssen and Philips.
Erika B. Rosenzweig reports research funding from Janseen/Actelion, Bayer, Gilead, Lung Rx and SonVie.
The remaining authors have nothing to disclose
Tweet: Case of RV thrombus treated with systemic thrombolysis in COVID-19. Is VTE more common in COVID-19? Implications for the PERT team
- Received April 28, 2020.
- Revision received May 14, 2020.
- Accepted May 20, 2020.